Galmed Pharmaceuticals Ltd., a biopharmaceutical company operating within the health care sector, specializes in the development and commercialization of treatments for liver diseases and cholesterol gallstones. The company is a key player in the biotechnology industry and offers its products to the healthcare and medical industries. Galmed Pharmaceuticals is publicly traded on the Nasdaq stock exchange, having gone public on March 13, 2014. The company’s official website can be accessed at www.galmedpharma.com .
As of December 18, 2025, Galmed Pharmaceuticals’ stock closed at 0.851 USD. Over the past 52 weeks, the company’s share price has experienced significant fluctuations, reaching a high of 3.61 USD on January 2, 2025, and a low of 0.745 USD on November 19, 2025. These fluctuations reflect the dynamic nature of the biotechnology sector and the challenges faced by companies in this industry.
The company’s financial metrics indicate a challenging economic environment. Galmed Pharmaceuticals currently has a negative price-to-earnings (P/E) ratio of -0.31, which suggests that the company is not generating positive earnings. Additionally, the price-to-book (P/B) ratio stands at 0.301, indicating that the market valuation of the company is below its book value. This valuation suggests that investors may have concerns about the company’s future profitability and growth prospects.
In terms of recent developments, Galmed Pharmaceuticals announced on December 8, 2025, that it will present a late-breaking abstract at the HEP-DART 2025 meeting. This presentation is an opportunity for the company to showcase its research and developments in the field of liver diseases and cholesterol gallstones, potentially attracting interest from investors and partners in the healthcare industry.
With a market capitalization of 4,660,000 USD, Galmed Pharmaceuticals remains a relatively small player in the biotechnology sector. However, its focus on niche areas such as liver diseases and cholesterol gallstones positions it uniquely within the market. The company’s ability to innovate and develop effective treatments in these areas will be crucial for its future growth and financial performance.
Overall, Galmed Pharmaceuticals Ltd. continues to navigate the complexities of the biotechnology industry, striving to advance its research and development efforts while addressing the financial challenges reflected in its current market valuation.
